Clinical trial Recruiting at 1 site Interventional Ages 18 to 50 Women only

Using virtual reality glasses for women with preterm membrane rupture

Official title: The Effect of Virtual Reality Glass Use on Fetal Health Anxiety, Prenatal Distress, and Maternal-Fetal Attachment in Women With Premature Rupture of Membranes: A Randomized Controlled Trial

Run by Selcuk University · NCT07660393 · Data updated 2026-11-12

This trial tests whether wearing virtual reality glasses with nature videos helps reduce fetal health anxiety and prenatal distress and improve maternal-fetal attachment in first-time pregnant women with PPROM.

Quick facts

Study typeInterventional
Ages18 Years to 50 Years
SexWomen only
Enrollment176 (estimated)
SponsorSelcuk University
Academic / other
Locations1 site (Konya)
StatusRecruiting
StartedJune 16, 2026
Main results expectedJanuary 1, 2027
Study endsJanuary 1, 2027
Registry record updatedAugust 11, 2026
Trial IDNCT07660393 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Nulliparous women aged 18 or older with PPROM between 24 and 37 weeks of gestation, singleton pregnancy, hospitalized for at least 3 days, and able to speak Turkish without visual/hearing impairment.

Probably not a fit

Women who do not experience reductions in anxiety or distress or who have adverse reactions to VR exposure may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized controlled trial will enroll 176 first-time pregnant women hospitalized with preterm premature rupture of membranes between 24 and 37 weeks of gestation. The intervention group will use a virtual reality headset to view nature-themed videos with natural sounds twice daily for three days, while the control group receives standard antenatal care. Outcomes will be measured with the Fetal Health Anxiety Scale, Prenatal Distress Questionnaire, and Prenatal Attachment Inventory. The study aims to see if VR exposure can lessen anxiety and distress and strengthen maternal-fetal bonding during a high-risk pregnancy.

Why it matters

Potential benefit: If successful, VR glasses could provide a simple, nonpharmacologic way to reduce anxiety and distress and enhance maternal-fetal attachment in PPROM pregnancies.

How similar studies have gone: Previous studies in other settings suggest VR can reduce anxiety and distress, but this specific PPROM-related, maternal-fetal attachment outcome is novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Being 18 years of age or older
* Being nulliparous
* Having a diagnosis of preterm premature rupture of membranes (PPROM)
* Being between 24 and 37 weeks of gestation
* Having a singleton pregnancy
* Being hospitalized in the ward for at least 3 days
* Having no visual or hearing impairment
* Being communicative and mentally and psychologically healthy
* Being able to speak and express oneself in Turkish

Exclusion Criteria:

* Having an additional diagnosis besides preterm premature rupture of membranes (PPROM) (e.g., preeclampsia, fetal distress, fetal anomalies, gestational diabetes, bleeding, etc.)
* Having a chronic disease (e.g., hypertension, diabetes mellitus, thyroid disorders, etc.)
* Having conceived through assisted reproductive technologies (ART)
* Having any skin infection.

Where it's running

  • Seyhan Çankaya
    Konya, Turkey (Türkiye)
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.